[Whole-body retention studies of 169Yb-citrate.--Estimation of radiation dose to humans from 169Yb-citrate (author's transl)].
For purpose of the estimation of the radiation dose to humans from 169Yb-citrate, the whole-body retention studies using five rats were carried out. Following intravenous administration of 169Yb-citrate, the whole-body activity was monitored for 40 days by the animal counter. The whole-body retention curve consisted of three components: the first with a 3.6 hours effective half-time, the second with an 154 hours effective half-time and the third with a 29.9 days effective half-time. Therefore it was assumed that 32% of the administered 169Yb-citrate clears from the kidney with a short biologic half-time (3.6hours), 18% remains in the liver and other soft tissues with a relatively long biologic half-time (194 hours) and 50% remains in the bone with a long biologic half-time (850 days). Based on these biological data and the MIRD Committe method, the average dose to the bone and whole-body were 20.8 rads/mCi and 4.5 rads/mCi respectively.
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism; D002951:Citrates; D006207:Half-Life; D008297:Male; D011829:Radiation Dosage; D011868:Radioisotopes; D051381:Rats; D013997:Time Factors; D014018:Tissue Distribution; D015018:Ytterbium / Q000378:metabolism*
D002951:Citrates; D011868:Radioisotopes; D015018:Ytterbium